• FK866 (APO866): Evidence, Context, and Limits

  2026-10-05

  A source-grounded overview of FK866 (APO866) as a NAMPT-focused research tool, with emphasis on NAD metabolism, hematologic cancer research, AML models, and the distinction between supplier-reported findings and peer-reviewed evidence on PARP inhibitor resistance.

• Cy5-Labeled mRNA: Context, Evidence and Limits

  2026-10-04

  A source-grounded overview of EZ Cap™ Cy5 EGFP mRNA (5-moUTP), its conceptual value in mRNA delivery and translation studies, and how supplier specifications compare with findings from a recent redox-responsive peptide coacervate study.

• How GLI2 Shapes Immune Evasion and ICB Resistance

  2026-10-03

  DeVito and colleagues identify GLI2 as a mechanistic link between mesenchymal transformation, WNT and prostaglandin signaling, and resistance to immune checkpoint blockade. The study supports a model in which GLI2 reshapes the tumor microenvironment by suppressing antigen-presenting and cytotoxic immune functions, while also highlighting the need for biomarker-guided validation beyond preclinical systems.

• Rhodamine B for Spatially Resolved Nanomedicine

  2026-10-02

  Rhodamine B can turn nanomedicine localization into a measurable fluorescence readout, but signal alone does not prove therapeutic delivery. This guide explains how to design, control, and interpret Rhodamine B assays using the trypsin-responsive pancreatitis nanomedicine study as a model.

• Lactate–GPR81 Signaling in Insulin-Independent Glucose Uptak

  2026-10-01

  The 2026 Cell Research study identifies L-lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and defines a GPR81–FARP1–RAC1 mechanism that promotes GLUT4 translocation. Its combination of metabolic perturbation, receptor genetics, pharmacological activation, exercise analysis, and human genetic data provides a framework for studying glucose control beyond canonical insulin–AKT signaling.

• Radiopathomics Predicts Gastric Cancer ICI Response

  2026-10-01

  This study developed an interpretable radiopathomics signature by integrating baseline computed tomography with digital H&E pathology images to predict response to immunotherapy-based combination therapy in gastric cancer. Across multicenter training, internal validation, and external validation cohorts, the signature showed stronger discrimination than several established biomarkers and linked treatment response with immune-regulatory biology.

• Reconstituting Chromatin Reorganization in Oocytes

  2026-09-30

  A 2024 preprint identifies RNA polymerase II degradation as a direct driver of the NSN-to-SN chromatin transition during mammalian oocyte growth. By combining pharmacological perturbation, proteostasis inhibitors, and targeted protein depletion, the study connects transcriptional silencing with nuclear architecture and developmental competence.

• D-N-Acetylgalactosamine Protocol & QC Guide

  2026-09-30

  D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for glycoprotein characterization and brain heteropolysaccharides analysis. It is appropriate for aqueous or validated DMSO workflows, but not for ethanol-dependent methods or long-term storage of prepared solutions.

• MTSEA-biotin C5669 for Assay Reliability

  2026-09-29

  Learn how to position MTSEA-biotin (SKU C5669) within cell viability, proliferation, and cytotoxicity workflows without confusing thiol labeling with a direct metabolic readout. This scenario-based guide emphasizes controls, compatibility testing, protocol optimization, and evidence-limited vendor selection.

• ABE9-SpRY for Bystander-Free Mouse Models

  2026-09-29

  The reference study combines the ABE9 adenine base-editing architecture with the PAM-flexible SpRY Cas9 nickase to improve precision in mouse disease-model generation. ABE9-SpRY produced the intended A-to-G substitutions at three of four tested targets, reached efficiencies of up to 96% in individual adult founders, and showed improved product purity and fewer detected off-target events than ABE8e-SpRY at the tested loci.

• Light-Inducible RNA Switches for Gene Therapy Control

  2026-09-28

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translational level, remaining inhibitory in darkness and permitting expression under blue or ambient light. In mouse models, LIRP-regulated AAV2 systems supported light-dependent metabolic intervention and reversible control of retinal VEGF inhibition, providing a proof of concept for more precisely timed gene therapies.

• Balsalazide Disodium for Colitis Imaging Research

  2026-09-28

  Balsalazide disodium is best known as a colon-activated 5-aminosalicylic acid prodrug, but radiolabeling research suggests a second use: studying how tracer signal localizes in ulcerated colon. This article examines the study’s assay-design implications, limitations, and practical controls for inflammation research.

• DiscoveryProbe™ Immunology/Inflammation Compound Library

  2026-09-27

  The DiscoveryProbe™ Immunology/Inflammation Compound Library provides a defined set of 295 bioactive small molecules for screening immune and inflammatory responses and prioritizing follow-up experiments. It is for research assays and target-validation workflows, not for diagnosis, treatment, or direct confirmation of a compound’s mechanism in a particular model.

• Citron OGD2 Links Iron, ROS, and Canker Resistance

  2026-09-26

  The study identifies Citron CmOGD2 as a contributor to resistance against citrus canker, linking iron uptake and reactive oxygen species to a likely ferroptosis-like defense response. It also reveals feedback regulation by CmENO2 and CmZAT10.1, and shows how the Xanthomonas effector pthA4 may disrupt that feedback to favor infection.

• Z-DEVD-FMK: Mapping Caspase Signaling in Tumors

  2026-09-25

  Z-DEVD-FMK is a cell-permeable caspase-3 inhibitor that can help dissect apoptotic signaling—but its broader target profile matters. This article connects inhibitor design to DR5-driven PD-L1 stabilization and shows how to interpret experiments without mistaking pathway perturbation for target specificity.

7841 records 2/523 page Previous Next 12345 下5页 Last page